Reuters: Global Markets: Hospira withdraws outlook on FDA warning, shares slip

Reuters: Global Markets Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com

Hospira withdraws outlook on FDA warning, shares slip Feb 14th 2013, 15:17 Thu Feb 14, 2013 10:17am EST (Reuters) - Injectible-drugs maker Hospira Inc (HSP.N) withdrew the 2013 profit and revenue outlook it gave on Wednesday after the U.S. health regulator imposed an import ban on some of its products. Hospira shares fell about 7 percent to $30.25 in morning trade on the New York Stock Exchange. The company said it expects the ban to hurt 2013 adjusted earnings by 5 cents to 15 cents per share. Hospira had forecast 2013 adjusted earnings of $2.05 to $2.20 per share, and a 1 percent to 3 percent rise in sales, on Wednesday. On a post-earnings call later the same day, Hospira said it received a notice over the quality of its medical devices from the U.S. Food and Drug Administration. The notification expanded an import alert issued on November 8, 2012 on Hospira's Symbiq infusion pump. The expansion prohibited the import of its Plum, GemStar and LifeCare PCA infusion pumps, which are manufactured in Hospira's Costa Rica facility, into the United States.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions